tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Relmada Therapeutics regains compliance with Nasdaq min bid price requirement

Relmada Therapeutics (RLMD) announced that on September 15, 2025 it received written notice from the Nasdaq Stock Market confirming that the Company has regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2).

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1